The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Lamprene
Clofazimine · CLOFAZIMINE 50 mg/1 · Capsule, Liquid Filled · Oral · Novartis Pharmaceuticals Corporation
NDC 00078-1049-05 · 100 CAPSULE, LIQUID FILLED in 1 BOTTLE · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- NDA019500
- TE code
- —
- Approval date
- Dec 15, 1986
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Clofazimine (Capsule, Liquid Filled)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | CLOFAZIMINE 50 mg/1 | Aug 12, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Lamprene — NDC 00078-1049-05," retrieved September 3, 2026, https://drugdashboards.com/drug/00078104905.
Free to cite with attribution — see how the data is put together.